Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing

Yantai, August 8, 2025 –- Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping® (Dulaglutide Injection), indi...

VOLUNTARY ANNOUNCEMENT DULAGLUTIDE INJECTION (BOYOUPING) APPROVED FOR MARKETING IN CHINA

PLACING OF NEW SHARES UNDER GENERAL MANDATE

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025

Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert

Recently, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), as a standing observer of the International Council for Harmonisation of Technical Requirements for P...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025

Articles of Association

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Boan Receives FDA IND Clearance for Its CD228-Directed ADC

Boan Biotech today announced that it has received the Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) to proceed with the planned clinical study of the novel investigational ...

VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR BA1302 IN THE U.S.